FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2068370462> ?p ?o ?g. }

• W2068370462 endingPage "62" @default.
• W2068370462 startingPage "55" @default.
• W2068370462 abstract "Based upon promising preclinical and phase 1 trial results, combined flavopiridol and cisplatin therapy was evaluated in patients with ovarian and primary peritoneal cancers.A two cohort phase 2 trial of cisplatin (60 mg/m2 IV) immediately followed by flavopiridol (100 mg/m2 IV, 24 h infusion; 21 day cycles) was undertaken in patients with recurrent platin-sensitive or platin-resistant disease (progression>vs. ≤6 months following prior platin-based therapy). Measurable disease (RECIST)--or evaluable disease plus CA125>2X post-treatment nadir--and ECOG performance≤2 were required.Forty-five patients were enrolled between December 23, 2004 and February 25, 2010: 40 platin-resistant (Group 1), and 5 platin-sensitive (Group 2). In Group 1, the median number of treatment cycles was 3 (range 2-12). Only 10% of patients incurred grade 4 toxicities, but grade 3 toxicities were common (65%): neutropenia (17.5%); nausea (12.5%); vomiting, fatigue, thrombosis, anemia (10% each). Seven patients (17.5%) achieved a confirmed response (1 CR, 6 PR; median duration 118 days); ten additional patients (25%) attained maintained stable disease. Median time to progression was 4.3 months; overall survival was 16.1 months. Pilot translational studies assessed ascites flavopiridol level; surrogate marker studies were uninformative. In Group 2, although 4 of 5 patients responded (2 confirmed PRs with median time to progression, 10.8 months and median overall survival 20.6 months) the cohort was closed due to poor accrual.The assessed flavopiridol and cisplatin regimen displayed clinical activity in platin resistant and sensitive ovarian/primary peritoneal cancers, meriting further study." @default.
• W2068370462 created "2016-06-24" @default.
• W2068370462 creator A5007537630 @default.
• W2068370462 creator A5014339455 @default.
• W2068370462 creator A5016095265 @default.
• W2068370462 creator A5022282741 @default.
• W2068370462 creator A5022511085 @default.
• W2068370462 creator A5027165899 @default.
• W2068370462 creator A5036167325 @default.
• W2068370462 creator A5044497657 @default.
• W2068370462 creator A5045588395 @default.
• W2068370462 creator A5046795592 @default.
• W2068370462 creator A5059003210 @default.
• W2068370462 creator A5065411475 @default.
• W2068370462 creator A5069976109 @default.
• W2068370462 creator A5070672137 @default.
• W2068370462 creator A5073636065 @default.
• W2068370462 creator A5077726813 @default.
• W2068370462 creator A5084674411 @default.
• W2068370462 creator A5091001750 @default.
• W2068370462 creator A5091553384 @default.
• W2068370462 date "2012-10-01" @default.
• W2068370462 modified "2023-09-26" @default.
• W2068370462 title "A Phase 2 Trial of Flavopiridol (Alvocidib) and Cisplatin in Platin-Resistant Ovarian and Primary Peritoneal Carcinoma: MC0261" @default.
• W2068370462 cites W1960327677 @default.
• W2068370462 cites W1965734230 @default.
• W2068370462 cites W1967715255 @default.
• W2068370462 cites W1968807523 @default.
• W2068370462 cites W1973932751 @default.
• W2068370462 cites W1978427220 @default.
• W2068370462 cites W2001221382 @default.
• W2068370462 cites W2011857790 @default.
• W2068370462 cites W2018505775 @default.
• W2068370462 cites W2026171286 @default.
• W2068370462 cites W2030437687 @default.
• W2068370462 cites W2036015352 @default.
• W2068370462 cites W2044929474 @default.
• W2068370462 cites W2055948876 @default.
• W2068370462 cites W2072697228 @default.
• W2068370462 cites W2075668200 @default.
• W2068370462 cites W2100726270 @default.
• W2068370462 cites W2103554051 @default.
• W2068370462 cites W2113230118 @default.
• W2068370462 cites W2135390756 @default.
• W2068370462 cites W2150508157 @default.
• W2068370462 cites W2151672555 @default.
• W2068370462 cites W2153291245 @default.
• W2068370462 cites W2162645256 @default.
• W2068370462 cites W2166750426 @default.
• W2068370462 doi "https://doi.org/10.1016/j.ygyno.2012.05.030" @default.
• W2068370462 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4127485" @default.
• W2068370462 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22664059" @default.
• W2068370462 hasPublicationYear "2012" @default.
• W2068370462 type Work @default.
• W2068370462 sameAs 2068370462 @default.
• W2068370462 citedByCount "48" @default.
• W2068370462 countsByYear W20683704622013 @default.
• W2068370462 countsByYear W20683704622014 @default.
• W2068370462 countsByYear W20683704622015 @default.
• W2068370462 countsByYear W20683704622016 @default.
• W2068370462 countsByYear W20683704622017 @default.
• W2068370462 countsByYear W20683704622018 @default.
• W2068370462 countsByYear W20683704622019 @default.
• W2068370462 countsByYear W20683704622020 @default.
• W2068370462 countsByYear W20683704622021 @default.
• W2068370462 countsByYear W20683704622022 @default.
• W2068370462 countsByYear W20683704622023 @default.
• W2068370462 crossrefType "journal-article" @default.
• W2068370462 hasAuthorship W2068370462A5007537630 @default.
• W2068370462 hasAuthorship W2068370462A5014339455 @default.
• W2068370462 hasAuthorship W2068370462A5016095265 @default.
• W2068370462 hasAuthorship W2068370462A5022282741 @default.
• W2068370462 hasAuthorship W2068370462A5022511085 @default.
• W2068370462 hasAuthorship W2068370462A5027165899 @default.
• W2068370462 hasAuthorship W2068370462A5036167325 @default.
• W2068370462 hasAuthorship W2068370462A5044497657 @default.
• W2068370462 hasAuthorship W2068370462A5045588395 @default.
• W2068370462 hasAuthorship W2068370462A5046795592 @default.
• W2068370462 hasAuthorship W2068370462A5059003210 @default.
• W2068370462 hasAuthorship W2068370462A5065411475 @default.
• W2068370462 hasAuthorship W2068370462A5069976109 @default.
• W2068370462 hasAuthorship W2068370462A5070672137 @default.
• W2068370462 hasAuthorship W2068370462A5073636065 @default.
• W2068370462 hasAuthorship W2068370462A5077726813 @default.
• W2068370462 hasAuthorship W2068370462A5084674411 @default.
• W2068370462 hasAuthorship W2068370462A5091001750 @default.
• W2068370462 hasAuthorship W2068370462A5091553384 @default.
• W2068370462 hasBestOaLocation W20683704622 @default.
• W2068370462 hasConcept C121608353 @default.
• W2068370462 hasConcept C126322002 @default.
• W2068370462 hasConcept C141071460 @default.
• W2068370462 hasConcept C143998085 @default.
• W2068370462 hasConcept C2776694085 @default.
• W2068370462 hasConcept C2777063308 @default.
• W2068370462 hasConcept C2778239845 @default.
• W2068370462 hasConcept C2780427987 @default.
• W2068370462 hasConcept C2780580376 @default.
• W2068370462 hasConcept C2780852908 @default.

• next